Proteomic screening for pancreatic cancer antigen and development of antibody-based medicine.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25860575
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: National Institutes of Biomedical Innovation, Health and Nutrition
• Principal Investigator: SERADA SATOSHI 国立研究開発法人医薬基盤・健康・栄養研究所, 免疫シグナルプロジェクト, 研究員 (50463302)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 癌 / プロテオーム / タンパク質 / 抗体医薬

Outline of Final Research Achievements

By quantitative proteomic approach, cell surface membrane proteins were screened by comparing normal human pancreatic epithelial cells and pancreatic carcinoma cells. Elevated expression levels of the candidate cancer antigen was confirmed by immunohistochemical staining analysis using pancreatic carcinoma tissue sections. We developed novel monoclonal antibody targeting this antigen and found that some clone represented internalization into cells. When in vitro antibody-drug conjugate (ADC) assay was performed using primary antibody and second antibody, which was conjugated with tubulin inhibitor, the value was IC50 was less than 1 nM against antigen positive pancreatic carcinoma cells. We confirmed specific anti-tumor effect of the monoclonal antibody by ADC toward pancreatic carcinoma.

Free Research Field

腫瘍免疫学